Disparities in breast cancer outcomes between Caucasian and African American women: A model for describing the relationship of biological and nonbiological factors

Breast Cancer Research

Volumn 15, Issue 3, 2013, Pages

  Danforth, David N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; CELL CYCLE PROTEIN; GROWTH FACTOR; HORMONE; ORAL CONTRACEPTIVE AGENT;

AFRICAN AMERICAN; BREAST CANCER; BREAST FEEDING; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CAUCASIAN; COMORBIDITY; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; EDUCATION; GENE EXPRESSION; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH DISPARITY; HEALTH INSURANCE; HUMAN; INCOME; LACTATION; MAMMOGRAPHY; MARRIAGE; MULTIPARA; OBESITY; ONSET AGE; OUTCOME ASSESSMENT; REVIEW; SOCIOECONOMICS; THERAPY DELAY; TUMOR SUPPRESSOR GENE; BLACK PERSON; BREAST NEOPLASMS; FEMALE; GENETICS; PATHOLOGY; TREATMENT OUTCOME; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGE OF ONSET; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84879841101     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3429     Document Type: Review

References (100)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Thun M, Ward E. Cancer Facts and Figures for African Americans 2011-2012 , http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027765.pdf
3. Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev 2005, 14:2147-2153. 10.1158/1055-9965.EPI-04-0944, 16172224.
4. Hall IJ, Moorman PG, Millikan RC, Newman B. Comparative analysis of breast cancer risk factors among African-American women and White women. Am J Epidemiol 2005, 161:40-51. 10.1093/aje/kwh331, 15615914.
5. Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, Austin D, Muss H, Hunter CP, Redmond C, Sobhan M. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 1994, 3:127-135.
6. Weiss SE, Tartter PI, Ahmed S, Brower ST, Brusco C, Bossolt K, Amberson JB, Bratton J. Ethnic differences in risk and prognostic factors for breast cancer. Cancer 1995, 76:268-274. 10.1002/1097-0142(19950715)76:2<268::AID-CNCR2820760217>3.0.CO;2-1, 8625102.
7. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005, 97:439-448. 10.1093/jnci/dji064, 15770008.
8. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011, 43:1210-1214. 10.1038/ng.985, 3279120, 22037553.
9. Kato I, Cichon M, Yee CL, Land S, Korczak JF. African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer. Cancer Epidemiol 2009, 33:24-30. 10.1016/j.canep.2009.04.009, 2761149, 19679043.
10. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 1995, 55:3757-3758.
11. Ray M, Polite BN. Triple-negative breast cancers: a view from 10,000 feet. Cancer J 2010, 16:17-22. 10.1097/PPO.0b013e3181d3eef5, 20164686.
12. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 2002, 73:45-59. 10.1023/A:1015220420400, 12083631.
13. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994, 86:705-712. 10.1093/jnci/86.9.705, 7908990.
14. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 2009, 169:1251-1259. 10.1093/aje/kwp036, 2727208, 19318616.
15. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6. 10.1186/bcr1639, 1851385, 17239243.
16. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001, 92:37-45. 10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F, 11443607.
17. Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, Coates RJ, Eley JW. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004, 100:2533-2542. 10.1002/cncr.20279, 15197793.
18. Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, Yfantis HG, Tsai YC, Williams EH, Lee DH, Stephens RM, Weissman AM, Ambs S. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS ONE 2009, 4:e4531. 10.1371/journal.pone.0004531, 2638012, 19225562.
19. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009, 113:357-370. 10.1007/s10549-008-9926-3, 18324472.
20. Gukas ID, Girling AC, Mandong BM, Prime W, Jennings BA, Leinster SJ. A comparison of clinicopathological features and molecular markers in british and nigerian women with breast cancer. Clin Med Oncol 2008, 2:347-351. 3161669, 21892296.
21. Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett E, Parmigiani G, Broome C, Sukumar S. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res 2004, 10:2052-2057. 10.1158/1078-0432.CCR-03-0514, 15041725.
22. Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S. p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol 2010, 17:1398-1405. 10.1245/s10434-009-0889-3, 20049641.
23. Loo LW, Wang Y, Flynn EM, Lund MJ, Bowles EJ, Buist DS, Liff JM, Flagg EW, Coates RJ, Eley JW, Hsu L, Porter PL. Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat 2011, 127:297-308. 10.1007/s10549-010-1297-x, 3224104, 21264507.
24. Jiang Y, Cui L, Chen WD, Shen SH, Ding LD. The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data. PLoS ONE 2012, 7:e36780. 10.1371/journal.pone.0036780, 3355150, 22615811.
25. Boyer-Chammard A, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. Cancer Detect Prev 1999, 23:463-473. 10.1046/j.1525-1500.1999.99049.x, 10571656.
26. Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer 2000, 88:114-123. 10.1002/(SICI)1097-0142(20000101)88:1<114::AID-CNCR16>3.0.CO;2-J, 10618613.
27. Adams SA, Butler WM, Fulton J, Heiney SP, Williams EM, Delage AF, Khang L, Hebert JR. Racial disparities in breast cancer mortality in a multiethnic cohort in the Southeast. Cancer 2011, 118:2693-2699. 3269560, 21953316.
28. Zaloznik AJ. Breast cancer stage at diagnosis: Caucasians versus Afro-Americans. Breast Cancer Res Treat 1995, 34:195-198. 10.1007/BF00689710, 7579483.
29. Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, Schoenberg JB, Brinton LA. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003, 14:151-160. 10.1023/A:1023006000760, 12749720.
30. Johnson ET. Breast cancer racial differences before age 40 - implications for screening. J Natl Med Assoc 2002, 94:149-156. 2594112, 11918384.
31. Kurian AW, Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 2010, 12:R99. 10.1186/bcr2780, 3046442, 21092082.
32. Aziz H, Hussain F, Sohn C, Mediavillo R, Saitta A, Hussain A, Brandys M, Homel P, Rotman M. Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol 1999, 22:436-440. 10.1097/00000421-199910000-00002, 10521053.
33. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, Jatoi I. Racial disparities in breast cancer outcome: insights into host-tumor interactions. Cancer 2007, 110:1880-1888. 10.1002/cncr.22998, 17876835.
34. Ruiz-Narvaez EA, Rosenberg L, Cozier YC, Cupples LA, Adams-Campbell LL, Palmer JR. Polymorphisms in the TOX3/LOC643714 locus and risk of breast cancer in African-American women. Cancer Epidemiol Biomarkers Prev 2010, 19:1320-1327. 10.1158/1055-9965.EPI-09-1250, 2866101, 20406955.
35. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354:270-282. 10.1056/NEJMra050776, 16421368.
36. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16(Suppl 1):61-70.
37. Loden M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H, Landberg G. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002, 21:4680-4690. 10.1038/sj.onc.1205578, 12096344.
38. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996, 74:874-880. 10.1038/bjc.1996.451, 2074748, 8826852.
39. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007, 110:876-884. 10.1002/cncr.22836, 17620276.
40. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 1994, 73:2147-2156. 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5, 8156519.
41. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993, 85:200-206. 10.1093/jnci/85.3.200, 8423624.
42. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007, 120:3163-3172. 10.1242/jcs.010389, 17878233.
43. Krop I, Parker MT, Bloushtain-Qimron N, Porter D, Gelman R, Sasaki H, Maurer M, Terry MB, Parsons R, Polyak K. HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res 2005, 65:9659-9669. 10.1158/0008-5472.CAN-05-1663, 16266985.
44. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008, 26:3324-3330. 10.1200/JCO.2007.14.2471, 18612148.
45. Azim HA, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012, 18:1341-1351. 10.1158/1078-0432.CCR-11-2599, 22261811.
46. Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 2007, 14:2994-3003. 10.1245/s10434-007-9477-6, 17647064.
47. Albain S, Barlow WE, Shak S, Hortobagyi GN, Hayes DF. Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer. J Clin Oncol 2010, 28(Suppl):511.
48. Bruzzi P, Negri E, La VC, Decarli A, Palli D, Parazzini F, Del Turco MR. Short term increase in risk of breast cancer after full term pregnancy. BMJ 1988, 297:1096-1098. 10.1136/bmj.297.6656.1096, 1834877, 3143438.
49. Pathak DR, Osuch JR, He J. Breast carcinoma etiology: current knowledge and new insights into the effects of reproductive and hormonal risk factors in black and white populations. Cancer 2000, 88:1230-1238. 10.1002/(SICI)1097-0142(20000301)88:5+<1230::AID-CNCR9>3.0.CO;2-F, 10705360.
50. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA 2004, 101:15166-15171. 10.1073/pnas.0405881101, 524067, 15353581.
51. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010, 11:530-542. 3113287, 20472501.
52. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123-139. 10.1007/s10549-007-9632-6, 2443103, 17578664.
53. Li R, Fridinger F, Grummer-Strawn L. Racial/ethnic disparities in public opinion about breastfeeding: the 1999-2000 healthstyles surveys in the United States. Adv Exp Med Biol 2004, 554:287-291. 10.1007/978-1-4757-4242-8_24, 15384584.
54. Baquet CR, Mishra SI, Commiskey P, Ellison GL, DeShields M. Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc 2008, 100:480-488. 3603001, 18507200.
55. Hunter CP. Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer 2000, 88:1193-1202. 10.1002/(SICI)1097-0142(20000301)88:5+<1193::AID-CNCR3>3.0.CO;2-D, 10705354.
56. Lantz PM, Mujahid M, Schwartz K, Janz NK, Fagerlin A, Salem B, Liu L, Deapen D, Katz SJ. The influence of race, ethnicity, and individual socioeconomic factors on breast cancer stage at diagnosis. Am J Public Health 2006, 96:2173-2178. 10.2105/AJPH.2005.072132, 1698157, 17077391.
57. Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: seperating factors that affect diagnosis from factors that affect treatment. Cancer 2003, 97:2853-2860. 10.1002/cncr.11411, 12767100.
58. Reihani S, Akushevich I, Schildkraut J, Il'yasova D. Inflammatory breast cancer rates among different ethnic and rcial groups in the United States. Cancer Res 2011, 71(Suppl 1):3732.
59. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728. 10.1002/cncr.22618, 17387718.
60. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
61. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6. 10.1186/bcr1639, 1851385, 17239243.
62. Hunter CP, Redmond CK, Chen VW, Austin DF, Greenberg RS, Correa P, Muss HB, Forman MR, Wesley MN, Blacklow RS. Breast cancer: factors associated with stage at diagnosis in black and white women. Black/White Cancer Survival Study Group. J Natl Cancer Inst 1993, 85:1129-1137. 10.1093/jnci/85.14.1129, 8320742.
63. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005, 11:2156-2162. 10.1158/1078-0432.CCR-04-1810, 15788661.
64. Hoffman HJ, LaVerda NL, Levine PH, Young HA, Alexander LM, Patierno SR. Having health insurance does not eliminate race/ethnicity-associated delays in breast cancer diagnosis in the District of Columbia. Cancer 2011, 117:3824-3832. 10.1002/cncr.25970, 21815134.
65. Sheinfeld SN, Gorin J, Heck E, Gorin JE. Delay in breast cancer diagnosis by race/ethnicity. J Clin Oncol 2005, 23(Suppl):16S.
66. Lannin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS. Influence of socioeconomic and cultural factors on racial differences in latestage presentation of breast cancer. JAMA 1998, 279:1801-1807. 10.1001/jama.279.22.1801, 9628711.
67. Trock BJ. Breast cancer in African American women: epidemiology and tumor biology. Breast Cancer Res Treat 1996, 40:11-24. 10.1007/BF01805999, 8888149.
68. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
69. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005, 14:1108-1112. 10.1158/1055-9965.EPI-04-0394, 15894660.
70. Bandera EV, Chandran U, Zirpoli G, Ciupak G, Hwang H, McCann S, Pawlish K, Jandorf L, Bovbjerg D, Ambrosone C. Anthropometric factors and breast cancer among African American women participating in the Women's Circle of Health Study. Cancer Res 2012, 72:649.
71. Ownby HE, Frederick J, Russo J, Brooks SC, Swanson GM, Heppner GH, Brennan MJ. Racial differences in breast cancer patients. J Natl Cancer Inst 1985, 75:55-60.
72. Elmore JG, Moceri VM, Carter D, Larson EB. Breast carcinoma tumor characteristics in black and white women. Cancer 1998, 83:2509-2515. 10.1002/(SICI)1097-0142(19981215)83:12<2509::AID-CNCR15>3.0.CO;2-V, 9874456.
73. Furberg H, Millikan R, Dressler L, Newman B, Geradts J. Tumor characteristics in African American and white women. Breast Cancer Res Treat 2001, 68:33-43. 10.1023/A:1017994726207, 11678307.
74. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
75. Landberg G. Multiparameter analyses of cell cycle regulatory proteins in human breast cancer: a key to definition of separate pathways in tumorigenesis. Adv Cancer Res 2002, 84:35-56.
76. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002, 347:1566-1575. 10.1056/NEJMoa021153, 12432043.
77. Rodriguez-Gil J, Hill J, Allen G, Thomas V, Hu J. Racial/ethnic differences in double-strand break repair signaling in breast cancer. Cancer Res 2010, 70:4704.
78. Dowle CS, Owainati A, Robins A, Burns K, Ellis IO, Elston CW, Blamey RW. Prognostic significance of the DNA content of human breast cancer. Br J Surg 1987, 74:133-136. 10.1002/bjs.1800740221, 3815031.
79. Kallioniemi OP, Hietanen T, Mattila J, Lehtinen M, Lauslahti K, Koivula T. Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol 1987, 23:277-282. 10.1016/0277-5379(87)90071-X, 3595689.
80. Tarapore P, Fukasawa K. Loss of p53 and centrosome hyperamplification. Oncogene 2002, 21:6234-6240. 10.1038/sj.onc.1205707, 12214254.
81. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
82. Tammemagi CM. Racial/ethnic disparities in breast and gynecologic cancer treatment and outcomes. Curr Opin Obstet Gynecol 2007, 19:31-36. 10.1097/GCO.0b013e3280117cf8, 17218849.
83. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 2004, 96:1311-1321. 10.1093/jnci/djh253, 15339969.
84. Field TS, Buist DS, Doubeni C, Enger S, Fouayzi H, Hart G, Korner EJ, Lamerato L, Bachman DJ, Ellis J, Herrinton L, Hornbrook MC, Krajenta R, Liu L, Yao J. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr 2005, 35:88-95.
85. Henson DE, Chu KC, Levine PH. Histologic grade, stage, and survival in breast carcinoma: comparison of African American and Caucasian women. Cancer 2003, 98:908-917. 10.1002/cncr.11558, 12942556.
86. Hirschman J, Whitman S, Ansell D. The black:white disparity in breast cancer mortality: the example of Chicago. Cancer Causes Control 2007, 18:323-333. 10.1007/s10552-006-0102-y, 17285262.
87. Lu Y, Ma H, Malone KE, Norman SA, Sullivan-Halley J, Strom BL, Marchbanks PA, Spirtas R, Burkman RT, Deapen D, Folger SG, Simon MS, Press MF, McDonald JA, Bernstein L. Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol 2011, 29:3358-3365. 10.1200/JCO.2010.34.2048, 3164241, 21788570.
88. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996, 69:92-99. 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q, 8608989.
89. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol 2001, 32:89-94. 10.1053/hupa.2001.21141, 11172300.
90. Nielsen NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 1997, 14:295-304. 10.1038/sj.onc.1200833, 9018115.
91. Li HP, Ji JF, Hou KY, Lei YT, Zhao HM, Wang J, Zheng J, Liu JY, Wang MP, Xiao Y, Wang YF, Lu YY, Sun Y. Prediction of recurrence risk in early breast cancer using human epidermal growth factor 2 and cyclin A2. Chin Med J (Engl) 2010, 123:431-437.
92. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009, 15:3654-3662. 10.1158/1078-0432.CCR-08-3293, 2887710, 19470724.
93. Aaltonen K, Amini RM, Heikkila P, Aittomaki K, Tamminen A, Nevanlinna H, Blomqvist C. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer 2009, 100:1055-1060. 10.1038/sj.bjc.6604874, 2669992, 19293801.
94. Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 1995, 55:1485-1490.
95. Blaszyk H, Vaughn CB, Hartmann A, McGovern RM, Schroeder JJ, Cunningham J, Schaid D, Sommer SS, Kovach JS. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet 1994, 343:1195-1197. 10.1016/S0140-6736(94)92403-1, 7909871.
96. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD, DeWitty RL, Frederick WA. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg 2008, 247:463-469. 10.1097/SLA.0b013e31815d744a, 18376191.
97. van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EA, Stoto MA, Draisma G, de Koning HJ, Mandelblatt JS. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev 2011, 20:112-122. 10.1158/1055-9965.EPI-10-0944, 3075821, 21119071.
98. Daling JR, Malone KE, Doody DR, Anderson BO, Porter PL. The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev 2002, 11:235-241.
99. Wang Y, Zhou BP. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 2011, 30:603-611. 10.5732/cjc.011.10226, 21880181.
100. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics?. Cancer 2008, 112:171-180. 10.1002/cncr.23131, 2674622, 18040998.